Potential Financial Bias From Speakers at US Food and Drug Administration's Bone, Reproductive, and Urologic Drugs Advisory Committee Meetings

Johnson, Bradley S.; Roberts, Will; Riddle, Jonathan; Wayant, Cole; Scott, Jared; Vassar, Matt

doi:10.1016/j.urology.2019.11.042

Cited by 7 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have shown that financial relationships with pharmaceutical companies influence physicians’ behavior in prescribing drugs, [ 24 , 27 , 28 , 29 , 30 ] recommendations of clinical practice guidelines, [ 6 , 10 , 31 , 32 , 33 ] and comments on drugs in pharmaceutical advisory committees [ 34 , 35 , 36 , 37 ]. Pharmaceutical companies sometimes spend more payments for marketing less effective and less advantageous drugs [ 38 , 39 ] but with more harms to patients [ 40 , 41 ].…”

Section: Discussionmentioning

confidence: 99%

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Murayama

Kamamoto

Saito³

et al. 2022

IJERPH

View full text Add to dashboard Cite

Backgrounds: Conflict of interest with pharmaceutical companies is one of the most concerned issues in infectious diseases. However, there is a lack of whole picture of detailed payments in Japan. Methods: This retrospective study assessed financial relationships between pharmaceutical companies and all infectious disease specialists board-certified by the Japanese Association for Infectious Disease, using publicly disclosed payment data from 92 major pharmaceutical companies. Descriptive analyses were conducted for the payments. Payment trends were examined by the generalized estimating equations. Results: Of 1614 board-certified infection disease specialists, 1055 (65.4%) received a total of $17,784,070 payments, corresponding to 21,680 contracts between 2016 and 2019. The mean ± SD and median (interquartile range: IQR) were $16,857 ± $45,010 and $3183 ($938–$11,250) in payments. All board executive members of Japanese Association of Infectious Disease received higher payments averaging $163,792. There were no significant changes in payments per specialist (annual change rate: −1.4% [95% CI: −4.7–2.3%], p = 0.48) and prevalence of specialists with payments (annual change rate: −1.4% [95% CI: −3.1–0.2%], p = 0.093) over the four years. Conclusion: There were substantial financial relationships between pharmaceutical companies and board-certified infectious disease specialists in Japan. Furthermore, high ranked specialists such as those in the executive board had stronger financial ties with the companies.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Murayama

Kamamoto

Saito³

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…A number of studies have shown that financial relationships with pharmaceutical companies influence physicians' behavior in prescribing drugs, [26][27][28][29][30] recommending clinical guidelines, [5,8,[31][32][33] and commenting on drugs in pharmaceutical advisory committees. [34][35][36][37] Pharmaceutical companies sometimes spend more payments for marketing less effective and less advantageous drugs [38,39] but with more harms to patients. [40,41] Despite these influences, the trends of the physicians' acceptance of personal payments from industries are still common [17,42,43] and are even increasing in several specialties.…”

Section: Discussionmentioning

confidence: 99%

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Murayama

Kamamoto

Yamada

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective Conflict of interest with pharmaceutical companies is one of the most contentious issues in infectious diseases. However, there is a lack of whole picture of detailed payments in Japan. Study Design and Setting This retrospective study assessed financial relationships between pharmaceutical companies and all infectious disease specialists board-certified by the Japanese Association for Infectious Disease, using publicly disclosed payment data from 92 pharmaceutical companies. Descriptive analyses were conducted for the payments. Payment trends were examined by the generalized estimating equations. Results Of 1614 board-certified infection disease specialists, 1,055 (65.4%) received a total of $17,784,070 payments, corresponding to 21,680 instances between 2016 and 2019. The mean (SD) and median (IQR) were $16,857 ($45,010) and $3,183 ($938-$11,250) in payments. All board executive members of Japanese Association for Infectious Diseases received higher payments averaging $163,792. There were no significant changes in payments per specialist (annual change rate: -1.4% [95% CI: -4.7- 2.3%], p=0.48) and prevalence of specialists with payments (annual change rate: -1.4% [95% CI: -3.1-0.2%], p=0.093) over the four years. Conclusion There were substantial financial relationships between pharmaceutical companies and board-certified infectious disease specialists in Japan. Such personal payments must be restricted to a certain level to avoid potential conflict of interest.

show abstract

Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations

Nejstgaard

Bero²,

Hróbjartsson

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Potential Financial Bias From Speakers at US Food and Drug Administration's Bone, Reproductive, and Urologic Drugs Advisory Committee Meetings

Cited by 7 publications

References 14 publications

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations

Contact Info

Product

Resources

About